Welcome, Guest. Please login or register.
December 02, 2024, 08:59:03 am

Login with username, password and session length


Members
Stats
  • Total Posts: 55133
  • Total Topics: 4851
  • Online Today: 255
  • Online Ever: 3061
  • (September 25, 2024, 11:40:40 pm)
Users Online
Users: 1
Guests: 241
Total: 242

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: The "Economics" of Hepatitis C  (Read 7027 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
The "Economics" of Hepatitis C
« on: December 01, 2015, 05:08:14 pm »
-Current estimates show that up to 3.9 million people are living with hepatitis C in the U.S. today.
-Today, the efficacy of hepatitis C treatment is upwards of 90% for most people.
-Right now, the discounted lifetime cost of treating 1 person with hepatitis C in the U.S. is $58,000.

At this point in time, we have an incredible opportunity to nearly eliminated hepatitis C in the United States by taking appropriate and timely steps. If we do this, hepatitis C could be a nonissue in this country by 2035.

Here’s how: http://www.hepmag.com/articles/2502_28097.shtml

Offline KimInTheForest

  • Member
  • Posts: 1,972
  • Believe in yourself
Re: The "Economics" of Hepatitis C
« Reply #1 on: December 01, 2015, 05:53:20 pm »
This article makes excellent points. One thing I am confused about...

The article says: HCV is "an epidemic impacting up to 3.9 million people in the U.S."

Later it says: "more than a million patients [will need] HCV treatment in the next 3 to 5 years in the U.S."

Why wouldn't all 3.9 million need treatment in the next 3-5 years? It seems to me that this article is still operating with a triage mentality of treating the most urgent first instead of treating everyone now, which the article otherwise seems to be advocating.

kim
Kim Goldberg (Nanaimo, BC)
1970s: Contracted HCV (genotype 3a)
2015: Cured with Harvoni + ribavirin (12 weeks)
MY STORY: https://pigsquash.wordpress.com/2016/01/28/undetectable-my-hep-c-story/

Offline Westy

  • Member
  • Posts: 17
Re: The "Economics" of Hepatitis C
« Reply #2 on: December 08, 2015, 07:08:46 am »

I am dumbfounded why so long and why so expensive ?

The patent expires in 2025 so the meds should only cost a few hundred bucks a course by then. US taxpayers paid for a lot of the development costs for Sofisbuvir just so they can be fleeced to the tune of 100's of billions by the drug companies.

The Economics of Hepatitis C are like this.

With Pharmasset we can look at the balance sheet immediately prior to Gilead's purchase. At the time the sunk capital cost (accumulated deficit) was $324 million. That's a lot of money, but nothing like the $7 billion valuation in the market (20x) or the sale price of $11 billion (33x).

That $324 million represents almost the ENTIRE development cost of this medication. There would have been another $50 million for the Phase 3 trials. Call it $400 million all in.

With some 613,000 people treated to date at around $50,000 per person the return is already north of $30 billion. That is 60 x the sunk cost in 3 years.

To treat the entire US population would be north of $200 billion. That is 500 x the sunk cost.

Sofisbuvir costs just 5 cents per dose to manufacture in India.

cheers
Gen 3a Started Sof Dac 16/10/15
Ribavirin Started 18/11/2015

V/L 19 Mill +
Hep C pos approx. 27 yrs
2 Week Bloods = Normal Ast Alt, V/L 16 :)
10/Dec/15    UND  Probably was at week 4

Non responder 2011 BMS (dac) Peg Rib

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.